系统性红斑狼疮中具有临床意义的免疫性血小板减少症:90例患者的回顾性队列研究
这项回顾性多中心研究纳入90例伴有具有临床意义的免疫性血小板减少症(ITPCS)的系统性红斑狼疮(SLE)患者,中位随访80个月。28%患者发生主要出血事件(MBG),其出血表现、血清浆膜炎和血栓形成更多,需要更多治疗线数、输血和住院。糖皮质激素和羟氯喹可使约三分之一患者获得总体缓解,多种治疗选择似乎可行。
要点
- SLE-ITPCS患者中28%发生主要出血事件,MBG患者出血评分更高且需更多治疗线数、输血和住院。
- 11例(12%)无出血事件的患者SLE表型更局限(皮肤和/或关节受累)。
- 糖皮质激素和羟氯喹可使约三分之一ITPCS患者获得总体缓解。
核心结论
- SLE-ITPCS患者血液学异常发生率高,发生MBG的患者发病率更高。
- 血小板减少症的管理高度异质,许多选择似乎可行。
研究设计与样本
- 回顾性多中心研究,纳入90例经历过至少1次ITPCS的SLE患者,ITPCS定义为伴有可归因出血性疾病和/或血小板计数<30×10^9/L的ITP,排除其他原因继发性血小板减少。
- 主要出血事件(MBG)定义为Khellaf评分>8和/或WHO评分>2。
主要发现
- 中位(范围)随访时间为80(6-446)个月。
- 25例(28%)患者发生MBG,其ITP诊断时出血更多、出血评分更高,随访期间血清浆膜炎和血栓形成更多,需要显著更多的治疗线数、输血和住院。
- 11例(12%)无出血事件的患者SLE表型显著更局限(皮肤和/或关节)。
- 患者平均(范围)接受4.2(1-11)线治疗。
- 利妥昔单抗(n=34)、硫唑嘌呤(n=19)、霉酚酸酯(n=8)、血小板生成素受体激动剂(n=16)和脾切除术(n=19)的中位无复发生存期分别为53、31.5、61、24.5和78个月。
关键数值与推荐
- ITPCS定义为ITP伴有可归因出血性疾病和/或血小板计数<30×10^9/L。
- MBG定义为Khellaf评分>8和/或WHO评分>2。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the characteristics, treatment and outcome of patients with immune thrombocytopenia with clinical significance (ITPCS) associated with SLE. METHODS: This retrospective multicentre study included SLE patients who experienced ≥1 ITPCS (defined as ITP with attributable bleeding disorders and/or a platelet count <30×109/l). Other causes of secondary thrombocytopenia were excluded. Major bleeding event (MBG) was defined as Khellaf score >8 and/or WHO score >2. RESULTS: A total of 90 patients were included, the median (range) follow-up duration was 80 (6-446) months. ITP was diagnosed before SLE in 25 patients. They presented a high rate of autoimmune haemolytic anaemia (15%), antiphospholipid antibody (62%) and antiphospholipid syndrome (19%). The 25 (28%) patients who experienced MBG had significantly more bleedings at ITP diagnosis and higher bleeding scores, and serositis and thrombosis during follow-up. They required significantly more treatment lines, transfusions and hospitalizations. The 11 (12%) patients who experienced no bleeding event presented a significantly more restricted SLE phenotype (cutaneous and/or articular). Patients received a mean (range) of 4.2 (1-11) treatment lines. Corticosteroids and HCQ allowed ITPCS overall response in one-third of patients. The median relapse-free survival of rituximab (n = 34), AZA (n = 19), MMF (n = 8), thrombopoietin-receptor agonists (n = 16) and splenectomy (n = 19) were 53, 31.5, 61, 24.5 and 78 months, respectively. Four patients experienced thrombotic events after splenectomy and one occurred under thrombopoietin-receptor agonist treatment. CONCLUSION: SLE-ITCS patients displayed a high rate of haematological abnormalities and MBG patients exhibited higher morbidity. Management of thrombocytopenia was highly heterogeneous and many options seem viable.
引用
- Roussotte M, Gerfaud-Valentin M, Hot A, et al. Immune thrombocytopenia with clinical significance in systemic lupus erythematosus: a retrospective cohort study of 90 patients. Rheumatology (Oxford). 2022. PMID: 34918048. doi:10.1093/rheumatology/keab925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。